May 23rd, 2007

For Drug Makers, a Downside to Full Disclosure

By Barry Meier
The New York Times

When GlaxoSmithKline settled a lawsuit three years ago with the State of New York over the antidepressant medication Paxil, the company agreed to take an unusual step: publicly disclosing the results of its clinical trials for Paxil and other drugs.

This week, GlaxoSmithKline learned what that greater disclosure could mean.

Read the full article here.

Comments

Add your own Comment

(optional)